Keyphrases
Blood Pressure Control
100%
ACE Inhibition
100%
Moexipril
100%
ACE Inhibitors
41%
Quinapril
25%
Ramipril
16%
Neuroprotective Effect
16%
Serum Levels
8%
Quality of Life
8%
Rat Model
8%
Metabolic Changes
8%
Estrogen
8%
Per Se
8%
Patient Demographics
8%
Lipids
8%
Hormone Replacement Therapy
8%
Blood Pressure
8%
Uric Acid
8%
Left Ventricular Mass
8%
Cardiovascular Risk
8%
Hypertensive Patients
8%
Antihypertensive Drugs
8%
Plasma Insulin
8%
Renin-angiotensin-aldosterone System
8%
Patients with Hypertension
8%
High Cardiovascular Risk
8%
Blood Glucose
8%
Endothelium
8%
Bone Resorption
8%
Renal Disease
8%
Cardioprotection
8%
Captopril
8%
Enalaprilat
8%
Jugular Vein
8%
Renal Insufficiency
8%
No Adverse Effect
8%
Neuronal Survival
8%
Lipid Membrane
8%
Lipophilicity
8%
Urinary Protein Excretion
8%
Endothelial Dysfunction
8%
Bone Metabolism
8%
ACE Activity
8%
Antioxidant Properties
8%
Renoprotective Effect
8%
Constrictor
8%
Free Radical Scavenging Property
8%
Bradykinin
8%
Ultrafiltration Coefficient
8%
Benazepril
8%
Arterial Distensibility
8%
Plasma ACE
8%
Vasoprotective
8%
Osteoprotective Effect
8%
Bradykinin B2 Receptor
8%
Life Data
8%
Pharmacology, Toxicology and Pharmaceutical Science
Moexipril
100%
Dipeptidyl Carboxypeptidase Inhibitor
41%
Cardiovascular Risk
16%
Neuroprotective Agent
16%
Quinapril
16%
Replacement Therapy
8%
Angiotensin
8%
Rat Model
8%
Uric Acid
8%
Kidney Failure
8%
Antihypertensive Agent
8%
Adverse Event
8%
Renin
8%
Aldosterone
8%
Antioxidant
8%
Captopril
8%
Ramipril
8%
Enalaprilat
8%
Kidney Disease
8%
Membrane Lipid
8%
Leporidae
8%
Lipophilicity
8%
Preclinical Study
8%
Free Radical
8%
Endothelial Dysfunction
8%
Bradykinin
8%
Benazepril
8%
Moexiprilat
8%
Ramiprilat
8%
Bradykinin B2 Receptor
8%
Quinaprilat
8%